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Domenico Ribatti7,8* and Girolamo Ranieri1Abstract
Background: Tryptase is a serine protease released from mast cells that plays a role in tumor angiogenesis. In this
study we aimed to evaluate serum tryptase levels in 105 female early breast cancer patients before (STLBS) and
after (STLAS) radical surgical resection, mast cell density positive to tryptase (MCDPT) and microvascular density
(MVD).
Methods: STLBS and STLAS were assessed using the UniCAP Tryptase Fluoroenzyme immunoassay. Tumor
sections were immunostained with a primary anti-tryptase antibody and an anti-CD-34 antibody by means of
immunohistochemistry.
Results: The mean ± 1 standard deviation STLBS and STLAS was 7.18 ± 2.63 μg/L, and 5.13 ± 2.21 respectively and a
significant difference between mean levels was found (p = 0.0001) by student t-test. A strong correlation between
STLBS and MVD (r = 0.81, p = 0.0001); STLBS and MCDPT (r = 0.69, p = 0.003); and MCDPT and MVD (r = 0.77; p = 0.0001)
was found.
Conclusions: Results demonstrated higher STLBS in breast cancer patients, indicating an involvement of MC tryptase
in breast cancer angiogenesis. Therefore, serum tryptase levels may play a role as a novel surrogate angiogenic marker
predictive of response to radical surgery in breast cancer patients. In this patients setting, it’s intriguing to hypothesize
that tryptase inhibitors might be evaluated in clinical trials.
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Published data suggest that mast cells (MCs) have a dual
role in the regulatory function between inflammatory
and tumor cells. Interestingly, MCs induce tumor devel-
opment and progression angiogenesis-mediated by means
of the release of various angiogenic molecules such as
Vascular Endothelial Growth Factor (VEGF), Fibroblast
Growth Factor-2 (FGF-2), tryptase, chymase. On the other* Correspondence: domenico.ribatti@uniba.it
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unless otherwise stated.hand, MCs may induce apoptosis of malignant cells by
means of the release of several cytokines such as
interleukin-4 and Tumour Necrosis Factor [1-5].
Several experimental studies have already demon-
strated that MCs are involved in tumor macroscopic ex-
pansion and development [6-9]. Interestingly, it has been
also shown that MCs density (MCD) is strongly related
to angiogenesis in animal and human malignancies
[3,9-22]. Among pro-angiogenic factors released from
MCs tryptase is one of the most powerful. It has been
demonstrated that tryptase induces in vitro micro-
vascular endothelial cells proliferation in the matrigelLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chick embryo chorioallantoic membrane [23-25].
Tryptase is an agonist of the proteinase-activated
receptor-2 (PAR-2) in vascular endothelial cells and
breast cancer cells that in turn stimulates their prolifera-
tion [24]. Tryptase also induces angiogenesis by release
of stored angiogenic factors bound to the extracellular
matrix [26-29]. Very little data have been published
regarding the role of tissue MCs density positive toTable 1 MCDPT and MVD expression, STLBS and STLAS levels
series of 105 breast cancer patients
Variable No. of
patients







< 58 years 48 25 (53)
≥ 58 years 57 33 (58)
Menopausal status
Premenopausal 43 24 (55)
Postmenopausal 62 36 (58)
Hystological type
Ductal 78 41 (52)
Lobular 27 14 (51)
Tumour size
pT1 49 26 (54)
pT2 36 16 (44)
pT3 20 12 (59)
Nodal status
pN0 44 19 (43)
pN1–2 61 29 (48)
Cytohistological grade
G1 37 19 (52)
G2 45 20 (44)
G3 23 12 (54)
Estrogen receptor status
Negative 29 16 (55)
Positive 76 37 (49)
Progesteron receptor status
Negative 34 19 (55)
Positive 71 36 (51)
c-erbB-2 status
Negative 69 37 (54)
Positive 36 22 (61)
*Median cut-off value: 8 cells per 400 field.
**Median cut-off value: 23 microvessels per 400 field.
***Median cut-off value: 6.4.
****Median cut-off value: 4.8.tryptase (MCDPT) in breast cancer (BC) angiogenesis
and development [7,8,30]. Moreover, no reports are
available about the role of serum tryptase in BC angio-
genesis and as a circulating predictive surrogate marker.
Therefore, in the present study we aimed to evaluate
serum tryptase levels in BC patients before (STLBS) and
after (STLAS) radical surgical resection and MCDPT
and microvascular density (MVD) in a series of tumor
tissue from early BC patients to correlate each to other.as a function of clinicopathological characteristics in a
tumours with
MVD** (%)
No. of tumours with high
STLBS*** (%)
No. of tumours with high
STLAS**** (%)
29 (58) 26 (55) 27 (56)
29 (51) 31 (54) 27 (48)
21 (49) 23 (53) 25 (59)
31 (50) 32 (52) 34 (55)
37 (47) 38 (49) 40 (51)
16 (58) 13 (48) 15 (55)
25 (55) 27 (55) 24 (49)
19 (52) 18 (51) 17 (47)
11 (54) 10 (50) 9 (47)
21 (48) 20 (46) 23 (52)
32 (53) 33 (54) 35 (58)
22 (60) 21 (58) 18 (48)
23 (51) 21 (47) 22 (49)
10 (45) 11 (50) 13 (56)
17 (58) 13 (46) 14 (55)
42 (55) 36 (48) 41 (54)
16 (47) 18 (53) 17 (50)
35 (49) 39 (55) 37 (52)
33 (48) 35 (51) 37 (53)
20 (55) 19 (52) 17 (48)
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gate marker of radical surgery has been also evaluated.
In this context tryptase inhibitors (gabexate and nafamo-
stat mesylate) might be evaluated in adjuvant clinical tri-
als as a new anti-angiogenic strategy.
Methods
Study populations
The clinicopathological features of the patients are sum-
marized in the Table 1. A series of 105 BC patients ob-
served at the Clinical Surgery Unit of the “Magna
Graecia” University of Catanzaro were selected. Biopsy
specimens were collected from 105 female BC patients
who had undergone BC surgery. Patients were selected
accordingly the presence of a primary, invasive breast
tumor (stage T1-T3), the presence or not of metastases
in axillary lymph nodes (stage N0-N2), the absence of
distant metastases (M0), the presence of unilateral
breast cancer and the absence of previous or concomi-
tant primary cancer. Patients were staged according to
the International Union Against Cancer Tumor Node
Metastasis (UICC-TNM) classification [31]. They not
received neo-adjuvant therapies nor other medications
that could interfere with serum tryptase levels. Surgi-
cal treatment performed was either a modified radical
mastectomy (39 patients in which the tumor had a
diameter >3 cm) or a quadrantectomy with axillaryFigure 1 Immunostaining of breast cancer sections with anti-tryptase
mast cell positive to tryptase. Big arrows indicate a single blood vessel with
magnification (0.19 mm2 area). (B) Arrows indicate a single red positive mi
MVD at x400 magnification (0.19 mm2 area). (C) Details of breast cancer se
arrows indicate a single red mast cell positive to tryptase, note the blue
red blood cell in their lumen. X1000 magnification in oil. (D) Details of b
Small arrow indicates two red positive microvessels. Big arrow indicates a cluslymphadenectomy. No patient was subjected to the in-
vestigation of sentinel lymph node. Following surgery,
a course of 5–6 weeks of radiation therapy (66 pa-
tients) was performed. On the basis of clinicopatho-
logical features patients were evaluated to receive
adjuvant hormonal therapy or chemotherapy or both.
Full ethical approval and signed consent from individual
patients were obtained to conduct the study. The full
name of ethics institutional committee review board that
approved our study is: University Hospital Ethics Commit-
tee “Mater Domini”, Germaneto, Catanzaro, Italy.
Sample preparation
Blood samples were collected one day before and one
day after surgery. Than samples were dispensed into test
tubes with serum separator tubes (Becton Dickinson
Vacutainer Systems Hemogard, Plymouth, UK) and left
for at least 30 min at room temperature. The samples
were subsequently centrifuged at 1,500 × g for 15 min at
room temperature and the supernatant was recovered.
Patient sera were frozen at −80°C. Starting the analytical
phase, sera were thawed to room temperature and mixed
thoroughly by vortexing at low speed in order to elimin-
ate any particulate matter affecting reproducible results.
Serum tryptase levels were measured by fluoro-enzyme-
immunoassay (FEIA) using Uni-CAP100 (Pharmacia
Diagnostics AB, Uppsala, Sweden).and anti-CD34 antibodies. (A) Small arrows indicate a single red
many red blood cells in their lumen. High MCDPT at x400
crovessel immunostained with a primary anti CD-34 antibody. High
ction immunostained with a primary anti-tryptase antibody. Small
nucleus of mast cell. Big arrows indicate a single microvessel with a
reast cancer section immunostained with a primary anti-CD-34 antibody.
ter of microvessels. X1000 magnification in oil.
Table 2 MCDPT, MVD, STLBS and STLAS means ±1














*8.35 ± 2.99 *30.11 ± 8.24 *7.18 ± 2.63 5.13 ± 2.21
*Mean ± 1 standard deviation.
t-test: p = 0.0001.
Pearson correlation between MVD and STLBS: r = 0.81; p = 0.0001.
Pearson correlation between MVD and MCDPT: r = 0.77; p = 0.0001.
Pearson correlation between STLBS and MCDPT: r = 0.69; p = 0.0003.
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The histological diagnosis was made on haematoxylin-
eosin-stained slides and histopathological grading was
performed according to the criteria described by Bloom
and Richardson, as well, moderately and poorly differen-
tiated state [32]. For the evaluation of MCDPT and
MVD a three-layer biotin-avidin-peroxidase system was
utilized [33]. Briefly, six-μm-thick serial sections of
formalin-fixed and paraffin-embedded biopsy tumour
were cut. Then, sections were microwaved at 500 W for
10 min, after which endogenous peroxidase activity was
blocked with 3% hydrogen peroxide solution. Adjacent
sections were stained with human-specific monoclonal
antibodies anti-tryptase (clone AA1; Dako, Glostrup,
Denmark) diluted 1:100 for 1 h at room temperature
and anti-CD34 (QB-END 10; Bio-Optica Milan, Italy) di-
luted 1:50 for 1 h at room temperature, respectively. The
bound antibody was visualized using a biotinylated sec-
ondary antibody, avidin-biotin peroxidase complex and
fast red. Nuclear counterstaining was performed with
Gill's haematoxylin no. 2 (Polysciences, Warrington, PA,
USA). The primary antibody was omitted in negative
controls.Figure 2 Tryptase levels before (STLBS) and after (STLAS) surgery in aMorphometrical assay
An image analysis system (Quantimet500 Leica, Wetzlar,
Germany) was utilized [33]. The five areas with higher
immunostaining (‘hot spots’) were selected at low mag-
nification and individual MCDPT (Figure 1A) and
MVD (Figure 1B) were counted at x400 magnification
(0.19 mm2 area). The details of MCDPT and MVD
were evaluated at x1000 magnification in oil (Figure 1C
and D, respectively).
Statistical analysis
MCDPT and MVD mean values ±1 standard deviations
(s.d.) were evaluated by two independent observers (V.Z.
and G.R.) for each tumor sample and in all series of sec-
tions. Correlations between STLBS, MCDPT, and MVD
were calculated using Pearson's (r) analysis. The correla-
tions between the above indexes and the clinicopathological
features listed in Table 1 were analyzed by the Chi-square
test. All statistical analyses were performed with the SPSS
statistical software package (SPSS, Inc., Chicago, IL).
Results
The mean ± 1 s.d. STLBS and STLAS were 7.18 ±
2.63 μg/L and 5.13 ± 2.21 μg/L respectively, and a sig-
nificant difference between mean levels was found (p =
0.0001) by t-test (Table 2, Figure 2). The mean ± 1 s.d.
of MCDPT and MVD was 8.35 ± 2.99 and 30.11 ± 8.24
respectively (Table 2). A significant correlation between
STLBS and MVD (r = 0.81, p = 0.0001), MCDPT and
MVD (r = 0.73; p = 0.001), STLBS and MCDPT (r = 0.60,
p = 0.003) was found (Figure 3).
Discussion
It has been well established that MCs are involved in
tumor development [6-9] angiogenesis-mediated both in
animal and human malignancies [9-22]. However, fewseries of 105 breast cancer patients.
Figure 3 Correlation analysis between: STLBS and MVD (r = 0.81,
p = 0.0001), MCDPT and MVD (r = 0.73; p = 0.001), MCDPT and
STLBS (r = 0.60, p = 0.003).
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in BC angiogenesis and development [7,8,30]. Interest-
ingly, no reports have been published regarding the role of
serum tryptase in BC angiogenesis and as a circulating
surrogate predictive marker.
In this pilot study we have shown for the first time
that STLBS strongly correlates with MCDPT and MVD
in primary tumor tissue. Our data also demonstratesthat STLAS significantly decrease in BC patients. Due
to the release of tryptase from MCs, we suggest that
MCDPT in primary BC tumor tissue represents the
main source of serum tryptase. In our hypothesis, if pri-
mary tumor tissue is completely removed STLAS should
decrease in one day due to their approximately 4-h long
life-cycle. For these reasons, we detected STLAS 24 h
before surgery to evaluate their possible role as a circulat-
ing surrogate marker suggesting the presence of tumor tis-
sue, and again 24 h after treatment to confirm its decrease
and, as a consequence, its possible expression of the ab-
sence of tumor tissue. We elaborate the background of
our hypothesis based on previously published pilot data,
which suggested an increase of MCDPT in primary tumor
tissue. In these studies MCDPT was correlated with
MVD, suggesting its role in BC angiogenesis [7,30].
Our data suggested an involvement of MCs and tryp-
tase in BC angiogenesis. Interestingly, published stud-
ies already demonstrated an involvement of tissue
MCDPT in other malignancies such as squamous car-
cinoma, gastrointestinal cancer, non-small cell lung cancer,
melanoma, and endometrial carcinoma [9,11,12,18,19].
However, the above studies did not focus on the changes
inSTLs before and after surgery, and no correlation be-
tween STLs, MCDPT and MVD was evaluated. It is re-
markable that tryptase released from MCs is involved
in tumor angiogenesis by several mechanisms. Firstly,
tryptase stimulates the formation of vascular tubes in
in vitro and in vivo experimental models; secondly,
tryptase is an agonist of the PAR-2 in vascular endo-
thelial cells that, in turn, induces angiogenesis [34];
thirdly, tryptase may stimulate the release of latent angio-
genic factors bound to the extracellular matrix [21,35].
Overall, the above data suggest that tryptase may be a po-
tential surrogate bio-marker of tumor angiogenesis which
is able to predict response to surgical treatment.Conclusions
If the primary source of tryptase production is no longer
existing, after 24 h a significant reduction in STLs should
be expected. If elevated STLs persist after surgery, this
would suggest that residual tumor tissue remains after
surgical resection or, alternatively, that unknown metasta-
ses are present. In this context, several tryptase inhibitors,
such as gabexate or nafamostat mesilate, may be evaluated
in future clinical trials as a new anti-tumor and anti-
angiogenic approach.
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